Life sciences

Cancers

Haematologica

pediatric blood & cancer

[1] Antitumor effects of rafoxanide in diffuse large B cell lymphoma via the PTEN/PI3K/Akt and JNK/c-Jun pathways.

[2] IRF4 translocation status in pediatric follicular and diffuse large B-cell lymphoma patients enrolled in Children's Oncology Group trials.

[3] Biological Features and Prognostic Impact of Bone Marrow Infiltration in Patients with Diffuse Large B-Cell Lymphoma.

[4] Clinicopathological and genetic features of limited-stage diffuse large B-cell lymphoma with late relapse: targeted sequencing analysis of gene alterations in the initial and late relapsed tumors.

[5] DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma: a single-arm, open-label, phase 2 study.

[6] primary extranodal diffuse large b-cell lymphoma of the prostate: a case report

[7] primary non-hodgkin lymphoma of the tongue base: the clinicopathology of seven cases and evaluation of hpv and ebv status

[8] systemic diffuse large b-cell lymphoma masquerading as neovascular glaucoma

[9] a tale of synchronous lung carcinoma and diffuse large b-cell lymphoma of ileum: a rare combination

[10] prognostic performance of lymphocyte-to-monocyte ratio in diffuse large b-cell lymphoma: an updated meta-analysis of eleven reports

[11] Perforated gastric diffuse large B-cell lymphoma: A case report and literature review

[12] [Expression and Clinical Significance of Serum LRG1 in Patients with Diffuse Large B-Cell Lymphoma before Treatment].

[13] Outpatient rituximab, ifosfamide, etoposide (R-IE) in patients older than 60 years with relapsed or refractory diffuse large B-cell lymphoma who are not candidates for stem cell transplantation.

[14] IRF4 translocation status in pediatric follicular and diffuse large B-cell lymphoma patients enrolled in Children's Oncology Group trials.

[15] Biological Features and Prognostic Impact of Bone Marrow Infiltration in Patients with Diffuse Large B-Cell Lymphoma.

[16] Artificial Intelligence Analysis of Gene Expression Data Predicted the Prognosis of Patients with Diffuse Large B-Cell Lymphoma.

[17] Clinicopathological and genetic features of limited-stage diffuse large B-cell lymphoma with late relapse: targeted sequencing analysis of gene alterations in the initial and late relapsed tumors.

[18] DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma: a single-arm, open-label, phase 2 study.

[19] Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study

[20] First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial

[21] Prognostic relevance of pretreatment quality of life in diffuse large B-cell lymphoma patients treated with rituximab-CHOP: Results from a prospective cohort study

[22] comparative molecular cell-of-origin classification of diffuse large b-cell lymphoma based on liquid and tissue biopsies

[23] primary uterine diffuse large b-cell lymphoma involving the urinary bladder with urinary cytology mimicking carcinomas: a case report

[24] the value of molecular techniques to diagnose ureaplasma urealyticum and nocardia farcinica pleuropneumonia in a patient with diffuse large b-cell lymphoma

[25] enhanced international prognostic index in japanese patients with diffuse large b-cell lymphoma

[26] two-dimensional matrix algorithm using detrended fluctuation analysis to distinguish burkitt and diffuse large b-cell lymphoma

[27] primary extranodal diffuse large b-cell lymphoma of the prostate: a case report

[28] systemic diffuse large b-cell lymphoma masquerading as neovascular glaucoma

[29] a tale of synchronous lung carcinoma and diffuse large b-cell lymphoma of ileum: a rare combination

[30] pleural fluid cytology of the polymorphous variant of ebv-positive diffuse large b-cell lymphoma: first report and distinction from a reactive process

[31] concomitant occurrence of multiple myeloma with diffuse large b-cell lymphoma

[32] determining the correlation of epstein-barr virus with diffuse large b-cell lymphoma by chromogenic in situ hybridization

[33] transformation of a cutaneous follicle center lymphoma to a diffuse large b-cell lymphoma—an unusual presentation

[34] multifocal extranodal involvement of diffuse large b-cell lymphoma

[35] long-term remission of primary bone marrow diffuse large b-cell lymphoma treated with high-dose chemotherapy rescued by in vivo rituximab-purged autologous stem cells

[36] prognostic performance of lymphocyte-to-monocyte ratio in diffuse large b-cell lymphoma: an updated meta-analysis of eleven reports

[37] prognostic significance of blood transfusion in elderly patients with primary diffuse large b-cell lymphoma

[38] an unusual case of extranodal diffuse large b-cell lymphoma infiltrating skeletal muscle: a case report and review of the literature

[39] Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling - Nature

[40] Diffuse Large B-Cell Lymphoma Presenting with Bilateral Renal Masses and Hematuria: A Case Report.

[41] Presentation of Diffuse Large B-Cell Lymphoma Relapse as a Penile Mass.

[42] A Rare Presentation of Acute Kidney Injury in Diffuse Large B-Cell Lymphoma: A Case Report.

[43] Efficacy of Axicabtagene Ciloleucel Compared to Historical Treatments for Relapsed/Refractory Diffuse Large B-Cell Lymphoma of Asian Descent: A Matching Adjusted Indirect Comparison of ZUMA-1 vs REAL-TREND.